A British medical journal, The Lancet Diabetes & Endocrinology, published this Correspondence item on July 18, 2017, “SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System”. The main point of that article is set forth in this excerpt: In summary, this pharmacovigilance analysis confirms that use of canagliflozin, but … [Read more...]
Invokana Shown to Have Heart Benefits, but Elevated Amputation Risks
Type 2 diabetes drug Invokana (canagliflozin) was the subject of the Canagliflozin Cardiovascular Assessment Study (CANVAS) and the CANVAS renal-end-points trial (CANVAS-R). While it was recently shown to have significant cardiovascular benefits, it also carries double the risk of lower-limb amputations. In terms of cardiovascular event … [Read more...]